

# JAMAICA

Number of new cases

**7 500**

Number of deaths

**4 632**

Number of prevalent cases (5-year)

**18 941**


## Statistics at a glance, 2022

	Males	Females	Both sexes
<b>Population</b>	1 480 345	1 504 742	2 985 087
<b>Incidence*</b>			
Number of new cancer cases	3 713	3 787	7 500
Age-standardized incidence rate	202.5	197.4	199.6
Risk of developing cancer before the age of 75 years (cum. risk %)	21.6	19.1	20.3
Top 3 leading cancers (ranked by cases)**	Prostate Colorectum Lung	Breast Corpus uteri Cervix uteri	Prostate Breast Colorectum
<b>Mortality*</b>			
Number of cancer deaths	2 423	2 209	4 632
Age-standardized mortality rate	122.9	110.6	116.6
Risk of dying from cancer before the age of 75 years (cum. risk %)	12.7	11.2	11.9
Top 3 leading cancers (ranked by deaths)**	Prostate Colorectum Lung	Breast Cervix uteri Colorectum	Prostate Breast Colorectum
<b>Prevalence*</b>			
5-year prevalent cases	8 400	10 541	18 941



## Top 5 most frequent cancers\*\*

**Males**




Total: 3 713

Rank	Cancer site	Number of cases	Percent
1st	Prostate	1 599	43.1%
2nd	Colorectum	484	13.0%
3rd	Lung	350	9.4%
4th	Stomach	189	5.1%
5th	NHL	146	3.9%
-	Others	945	25.5%

Number of new cases in 2022, males, all ages

**Females**




Total: 3 787

Rank	Cancer site	Number of cases	Percent
1st	Breast	1 327	35.0%
2nd	Corpus uteri	494	13.0%
3rd	Cervix uteri	376	9.9%
4th	Colorectum	309	8.2%
5th	Lung	195	5.1%
-	Others	1 086	28.7%

Number of new cases in 2022, females, all ages

**Both sexes**



Total: 7 500

Rank	Cancer site	Number of cases	Percent
1st	Prostate	1 599	21.3%
2nd	Breast	1 327	17.7%
3rd	Colorectum	793	10.6%
4th	Lung	545	7.3%
5th	Corpus uteri	494	6.6%
-	Others	2 742	36.6%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Prostate	1 599	1	21.3	10.4	829	1	17.9	3.3	3 799	256.6
Breast	1 327	2	17.7	7.1	684	2	14.8	3.6	4 072	270.6
Colorectum	793	3	10.6	2.3	509	3	11.0	1.4	2 106	70.6
Lung	545	4	7.3	1.7	461	4	10.0	1.4	706	23.7
Corpus uteri	494	5	6.6	3.3	160	7	3.5	0.97	1 661	110.4
Cervix uteri	376	6	5.0	2.0	236	5	5.1	1.4	1 149	76.4
Stomach	275	7	3.7	0.78	235	6	5.1	0.66	389	13.0
NHL	238	8	3.2	0.67	142	8	3.1	0.43	775	26.0
Leukaemia	175	9	2.3	0.46	132	9	2.9	0.36	512	17.2
Multiple myeloma	147	10	2.0	0.46	128	11	2.8	0.39	385	12.9
Pancreas	144	11	1.9	0.45	132	9	2.9	0.42	145	4.9
Bladder	125	12	1.7	0.34	67	15	1.4	0.17	345	11.6
Liver	110	13	1.5	0.31	96	12	2.1	0.25	150	5.0
Thyroid	109	14	1.5	0.37	17	20	0.37	0.05	341	11.4
Ovary	106	15	1.4	0.58	73	13	1.6	0.41	275	18.3
Oesophagus	76	16	1.0	0.21	72	14	1.6	0.20	100	3.4
Brain CNS	64	17	0.85	0.17	48	16	1.0	0.13	235	7.9
Larynx	59	18	0.79	0.17	39	17	0.84	0.12	169	5.7
Gallbladder	42	19	0.56	0.12	33	18	0.71	0.10	62	2.1
Kidney	42	19	0.56	0.12	25	19	0.54	0.08	127	4.3
Lip, oral cavity	32	21	0.43	0.08	15	21	0.32	0.04	85	2.9
Nasopharynx	25	22	0.33	0.07	14	22	0.30	0.04	71	2.4
Oropharynx	23	23	0.31	0.08	14	22	0.30	0.05	59	2.0
Penis	19	24	0.25	0.11	7	25	0.15	0.04	54	3.7
Hodgkin lymphoma	19	24	0.25	0.05	1	30	0.02	0.00	68	2.3
Salivary glands	14	26	0.19	0.06	5	26	0.11	0.02	41	1.4
Melanoma	14	26	0.19	0.04	9	24	0.19	0.03	42	1.4
Vulva	7	28	0.09	0.04	2	27	0.04	0.01	21	1.4
Vagina	6	29	0.08	0.03	1	30	0.02	0.01	16	1.1
Hypopharynx	5	30	0.07	0.02	2	27	0.04	0.01	9	0.30
Testis	5	30	0.07	0.03	0	32	0.00	0.00	20	1.4
Mesothelioma	2	32	0.03	0.01	2	27	0.04	0.01	2	0.07
<b>All cancers</b>	<b>7 500</b>	-	-	<b>20.3</b>	<b>4 632</b>	-	-	<b>11.9</b>	<b>18 941</b>	-
<b>All cancers excl. NMSC</b>	<b>7 429</b>	-	-	<b>20.1</b>	<b>4 623</b>	-	-	<b>11.9</b>	<b>18 714</b>	-

## Data source and methods

### Incidence



**Country-specific data source:** No data  
**Method:** Estimated from national mortality estimates by modelling, using mortality:incidence ratios derived from survival estimation

### Mortality

**Country-specific data source:** National (WHO)  
**Method:** National rates projected to 2022

### Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011–2020), and scaled using Human Development Index (HDI) ratios.



\* includes non-melanoma skin cancer (NMSC)

\*\* NMSC included in other cancers

Age standardization using world population ([see link](#))

## References

### Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

### Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. *Int J Cancer*. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

